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Abstract
Mitochondrial disorders are clinically and genetically heterogeneous and are associated with a variety of disease
mechanisms. Defects of mitochondrial protein synthesis account for the largest subgroup of disorders manifesting with
impaired respiratory chain capacity; yet, only a few have been linked to dysfunction in the protein components of the
mitochondrial ribosomes. Here, we report a subject presenting with dyskinetic cerebral palsy and partial agenesis of the
corpus callosum, while histochemical and biochemical analyses of skeletal muscle revealed signs of mitochondrial
myopathy. Using exome sequencing, we identified a homozygous variant c.215C>T in MRPS25, which encodes for a
structural component of the 28S small subunit of the mitochondrial ribosome (mS25). The variant segregated with the
disease and substitutes a highly conserved proline residue with leucine (p.P72L) that, based on the high-resolution structure
of the 28S ribosome, is predicted to compromise inter-protein contacts and destabilize the small subunit. Concordant with
the in silico analysis, patient’s fibroblasts showed decreased levels of MRPS25 and other components of the 28S subunit.
Moreover, assembled 28S subunits were scarce in the fibroblasts with mutant mS25 leading to impaired mitochondrial
translation and decreased levels of multiple respiratory chain subunits. Crucially, these abnormalities were rescued by
transgenic expression of wild-typeMRPS25 in the mutant fibroblasts. Collectively, our data demonstrate the pathogenicity of
the p.P72L variant and identify MRPS25 mutations as a new cause of mitochondrial translation defect.
Introduction
Mitochondrial disorders encompass a broad range of patholo-
gies, manifesting as tissue-specific or multisystemic diseases,
with onset at any stage of life. Genetically, they can arise from
lesions either in the mitochondrial genome (mtDNA) or in
nuclear genes required for the maintenance and function of
the mitochondria. The advent of next generation sequencing
has greatly accelerated the identification of causative disease
genes (1). Several of these are involved in the translation of the
13 proteins encoded by themtDNA that, although few in number,
are essential for oxidative phosphorylation (OXPHOS), and thus
for energy production. Central to the process of mitochondrial
protein synthesis is themitochondrial ribosome (mitoribosome).
In mammals, it comprises a large (mt-LSU, 39S) and a small
(mtSSU, 28S) subunit, together sedimenting as 55S particles.
The RNA components of the mitoribosome are encoded by
mtDNA, whereas the constituent polypeptides (MRPs), some 80
in number, derive from nuclear genes (2). Despite its complexity,
defects in the mitoribosome account for only a small minority
of mitochondrial translation disorders. To date, mutations in
MRPs have been reported for MRPS2, MRPS7, MRPS16, MRPS14,
MRPS22, MRPS23, MRPS34, MRPL3, MRPL12 and MRPL44 (3–14).
The clinical and biochemical phenotypes vary, but often
include neonatal or childhood onset with brain abnormalities,
cardiac involvement, increased lactate levels and multiple
respiratory chain deficiencies. Here, we report a homozygous
MRPS25 mutation in a patient presenting with mitochondrial
encephalomyopathy. Detailed functional analyses supported
the pathogenicity of the detected variant and demonstrate
the important role for MRPS25 in mitochondrial ribosome
function.
Results
Case report
The proband is a 25-year-old male, first child of healthy non-
consanguineous parents (Fig. 1A). He was born at term with a
birth weight of 2.5 kg following a normal pregnancy, although at
28 weeks intra-uterine growth restriction was detected. After
an uneventful perinatal period, psychomotor delay became
evident and, at 8 months his weight was 6.34 kg (beneath the
3rd centile) and head circumference was 40 cm (beneath the 3rd
centile). At 10 months, he exhibited poor head control, choreoa-
thetoid distal limb movements associated with increased
extensor tone and brisk reflexes. A brain magnetic resonance
imaging (MRI) scan at this time revealed partial agenesis of
corpus callosum and under-development of the frontal and
parietal temporal regions, while extensive investigation for
an underlying metabolic disorder, including measurement of
mucopolysaccharides and oligosaccharides, serum copper level,
white cell enzymes, very long chain fatty acids, carnitine levels,
pyruvate dehydrogenase activity and urine organic acid, failed
to detect any abnormalities. Karyotyping and echocardiogram
were normal too, while blood and CSF lactate showed borderline
values (2.8 mmol/l; 2.7 mmol/l, respectively, normal values
<2.1 mmol/l). Histochemical and biochemical analyses of
skeletal muscle were unremarkable,with the exception of amild
increase in lipid content in electron microscope images. Motor
milestones were subsequently delayed: he rolled at 18 months,
crawled at 48 months and could only walk a short distance
unaided at 9 years of age. His mobility performance was further
compromised by the development of hip dysplasia at 11 years,
for which surgery was required at 16 years, following which
mobility was reduced to a wheelchair. In the meantime, when
hewas 10 years old, hewas diagnosedwith adrenal insufficiency
and required hydrocortisone replacement. Since this time, the
clinical course has been progressive, with gradual worsening of
muscle fatigue and weakness and dysphagia. When reviewed
in our specialist mitochondrial clinic at 18 years of age, he had
short stature (150 cm) and microcephaly (head circumference
of 48.3 cm) and was alert and able to communicate using a
communication device. In the limbs, there was generalized
dystonia with global reduction in strength, symmetrically brisk
reflexes and downgoing plantar responses. Brain MRI confirmed
partial agenesis of the corpus callosum (Fig. 1B) and a repeat
of the metabolic investigations was normal, except for a mild
elevation of the plasma lactate (2.14mmol/l; normal value, 2.1).A
second muscle biopsy aged 19 years showed a uniform decrease
of cytochrome c oxidase (COX) histochemical staining, and
complex IV deficiencymeasured by spectrophotometric analysis
(0.007 Complex IV/Citrate Synthase ratio; normal values, 0.014–
0.034) and in-gel enzyme activity (Fig. 1C and D). Enzyme assays
of complex I and II+ III were within the normal range.
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Figure 1. Neuroradiological and histological findings. (A) Pedigree of the family;
the proband is indicated by the black arrow. (B) T1 sagittal brain MRI show-
ing partial agenesis of corpus callosum (yellow arrowheads). (C) Cytochrome
c oxidase staining (i) reveals a mild and generalized decreased activity with
rare fibres with subsarcolemmal mitochondrial aggregates typical of ‘ragged-
red’ alterations (succinate dehydrogenase, ii). (D) Complex IV in-gel activity is
decreased in the proband’s muscle sample.
Exome sequencing identified a homozygous mutation
in MRPS25 in the proband
With the hypothesis of amitochondrial aetiology of the disorder,
mtDNA was studied in patient samples (blood and muscle). The
analysis excluded pathogenic point mutations, rearrangements
or decreased mtDNA copy number (data not shown); therefore,
whole exome sequencing was undertaken in both the proband
and his parents.
A series of filtering steps (using Varaft platform (15)) were
applied to the identified variants and Trio-based analysis per-
formed, considering recessive, de-novo dominant and X-linked
inheritance pattern (Fig. 2A). A list of rare genetic variants was
generated (Supplementary Material, Table S1), but none of the
variants were consistent with the proband’s phenotype, includ-
ing the agenesis of the corpus callosum. Further filtering against
nuclear genes encodingmitochondrial proteins yielded two can-
didate genes: ABCB7 and MRPS25, encoding an ABC transporter
and a structural subunit of the mitochondrial ribosome, respec-
tively.
The variant inABCB7 (c.1472A>G; p.Y491C) on chromosomeX
has a high frequency in the population (Minor allele frequency,
MAF=0.001) and is predicted to be benign by multiple in silico
tools (Sorting Intolerant From Tolerant, SIFT 0.058, tolerate,
Polyphen2 HDIV 0.028, Benign; Polyphen2 HVAR 0.088, Benign).
In contrast, the homozygous nucleotide change in MRPS25,
c.215C>T; p.P72L, is extremely rare in the general population
(MAF 0.000008 in Genome Aggregation Database, gnomAD,
August 2018; absent in Exome variant server (ESP6500)), and
no homozygous cases are listed. Subsequent Sanger sequencing
of the family members confirmed the variant to be homozygous
in the proband’s DNA, whereas both parents and the healthy
sister were heterozygous carriers for the nucleotide change
(Fig. 2B). The p.P72 residue is highly conserved (Fig. 2C), and
its substitution by leucine is predicted to be damaging (SIFT
score=0.03; and PolyPhen-2 score=1 for both HVAR and HDVI).
The three-dimensional structure of the human ribosome (16)
places mS25 on the solvent side of the 28S subunit. Structural
modelling suggests that the P72L substitution is likely to
sterically hinder inter-protein contacts, particularly those with
uS17 (Fig. 2D), as well as resulting in a secondary destabilisation
of the folding of the essential strand-turn-strand in the mS25
protein core. The latter potentially compromises the assembly
or stability of the 28S mitochondrial ribosomal subunit. Thus,
both in silico analysis and modelling predict a deleterious effect
of the p.P72L substitution.
MRPS25-P72L is associated with low levels of MRPS25
protein and its 28S subunit partners
To investigate the effect of the mutation on the MRPS25 protein
levels we performed immunoblot analysis on fibroblast extracts
from the subject and two controls. The steady-state level of
MRPS25 in the proband’s fibroblasts was approximately one-
tenth of the level of the controls (Fig. 3A), indicating themutation
causes MRPS25 instability. Since MRPS25 is a structural subunit
of the 55S ribosome, we investigated whether other MRPS com-
ponents were affected by the lack of MRPS25. The abundance
of three other polypeptides of the 28S subunit, MRPS17, 22 and
29, was severely affected in the subject’s fibroblasts, while the
two components of the large mitochondrial ribosomal subunit
(MRPL44 and 45) analysedwere not decreased (Fig. 3A). The same
contrast between the large and small ribosomal subunits was
evident in the levels of the ribosomal RNAs: the 12S rRNA com-
ponent of the 28S subunit was 60% of the control value, while
the 16S rRNA of the 39S subunit was 1.5 times the control value
(Fig. 3B). Moreover, analysis of the mitochondrial ribosome pro-
file on sucrose gradients showed that, in the patient fibroblasts,
there was very little intact 28S subunit, and the residual MRPS
components were concentrated at the top of the gradient among
soluble and individual polypeptides, whereas the 39S subunit
was overall normal, albeit a small fraction distributed at a lower
buoyant density than controls (Fig. 3C, see also the outcome of
complementation, Fig. 6). Together, these data indicate that the
identified mutation principally affects the assembly or stability
of the small ribosomal subunits.
Mutant fibroblasts show impaired mitochondrial
protein synthesis and multiple respiratory chain defects
The scarcity of the mitoribosomes implies a reduced mitochon-
drial translation capacity that is expected to limit the produc-
tion of the mtDNA-encoded proteins required for the OXPHOS
system.Radiochemical labelling of newly synthesizedmitochon-
drial proteins demonstrated that mitochondrial translation was
compromised in cells with MRPS25-P72L (Fig. 4A). The impaired
translation was accompanied by decreases in the steady-state
levels of proteins of respiratory chain complexes I, III and IV
(Fig. 4B), with complex III being the least affected of the proton-
translocating enzymes of the respiratory chain (Fig. 4A and B).
In contrast, ATP synthase subunit 6 was translated in amounts
similar to control cells, suggesting that it takes priority. These
findings indicate that MRPS25 is required for mitochondrial
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Figure 2. Identification of a potential pathogenic MRPS25 mutation by exome sequencing. (A) Filtering of the identified variants was performed using Varaft platform
by comparing the proband’s and parents’ exomes. The analysis resulted in 42 genetic variants (de novo, recessive and X-linked), of which two were in genes encoding for
mitochondrial proteins. Only the c.215C>T change in MRPS25 was predicting as damaging (using SIFT and Polyphen tools). (B) Sanger sequencing confirmed that each
parent and the healthy sister were heterozygous (asterisk) for the mutation in MRPS25 while the affected patient was homozygous (arrow). (C) Sequencing alignment
of the human MRPS25 protein shows the evolutionary conservation of the Pro72. (D) The modelling of Pro72Leu (stick representation) mutation on the structure of
the human mitoribosome (PDBID: 3J9M) reveals that it is likely to sterically hinder the formation of interprotein contacts with uS17 (yellow) as well as result in a
potential destabilisation of the folding of the essential strand-turn-strand in the mS25 (cyan) protein core. The inset of the mitoribosomal structure illustrates the
relative position of uS17-mS25 (surface representation) on the small subunit (yellow cartoon); CP, central protuberance.
protein synthesis and that the impairment in translation in the
mutant fibroblasts results in decreased levels of the mitochon-
drial respiratory chain subunits.
Delivery of wild-typeMRPS25 rescues the mitochondrial
ribosomal assembly and OXPHOS protein levels
To further validate the pathogenicity of the MRPS25 c.215C>T;
p.P72L variant, we performed complementation studies by
introducing wild-type MRPS25 into immortalized fibroblasts.
Lentiviral-mediated expression of MRPS25 in control cells
resulted in marked cell death, suggesting a possible toxic effect
of the protein in a context of normal assembly of the 28S subunit.
In contrast to the controls, transgenicMRPS25waswell tolerated
in the cells with the MRPS25-P72L variant, where it resulted
in the restoration of MRPS levels (Fig. 5A) and the 28S subunit
(Fig. 6), accompanied by partial restoration of OXPHOS protein
levels (Fig. 5B). Collectively, these data establish the disease-
causing nature of the MRPS25 mutation.
Discussion
Defects in mitochondrial translation are among the earliest
known causes of mitochondrial disease, as many result from
mutations in the transfer RNA genes that are encoded inmtDNA
(17). However, over the course of three decades, pathological
mutations in many components of the mitochondrial protein
synthesis machinery have been identified, all of which are
encoded in nuclear DNA (18). Notwithstanding this, deleterious
mutations among the 80 structural proteins of themitoribosome
are still rare, numbering around 10 MRP genes; moreover, each
of these accounts for no more than a handful of patients
worldwide. The current study adds MRPS25 to the set of MRPs
whose loss of function causes human disease. Several lines
of evidence support the pathogenicity of the p.P72L variant:
first, the mutation results in a marked reduction of the MRPS25
protein (Fig. 3A); second, the lack of MRPS25 appears to destabi-
lize the entire small ribosomal subunit, which consequently
limits the rate of translation (Figs 3B and 4A), and OXPHOS
protein levels (Fig. 4B); finally, complementation of the proband’s
fibroblasts with wild-type MRPS25 restored the 28S subunit and
increased the levels of OXPHOS proteins (Figs 5 and 6).
MRPS25 is one of 15 structural subunits of the mitochondrial
28S that does not have a bacterial homolog (19). It is therefore
the result of the process by which the mitochondrial ribosomes
have diverged from their bacterial origin by reducing their RNA
content and increasing the number of proteins. The functional
role of MRPS25 has not previously been investigated; our current
analysis indicates that MRPS25 is essential to the assembly or
stability of the 28S subunit.
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Figure 3. MRPS25 mutation compromises the maintenance of normal 28S
subunit levels. (A) Steady state levels of small (MRPS25, MRPS17, MRPS29 and
MRPS22) and large (MRPL45, MRPL44) mitoribosomal subunits in controls (C1
and C2) and patient (P) total fibroblast extracts. Vinculin (VCL) is shown as a
loading control. The mean relative abundances are shown to the right based
on Fiji ImageJ densitometric analysis. Data are expressed as mean± standard
error of the mean of n=3 independent experiments, except MRPL27 and MRPS29
(n=2). Probability was determined using Welch’s t-test (ns =not significant,
P>0.05; ∗P< 0.05; ∗∗∗P< 0.001). (B) Relative 12S and 16S rRNA levels in patient-
derived fibroblasts. The data are representative of two independent experiments.
(C) Isokinetic sucrose gradients (10–30%) were used to analyze the distribution
of mitochondrial ribosome in total lysates from control (C) and patient (P)
fibroblasts. Mitochondrial ribosomal protein markers of the mt-SSU (MRPS27
and MRPS22) and the mt-LSU (MRPL13 and MRPL44) ribosomal subunits were
detected by immunoblotting. The data are representative of three independent
experiments.
While it was intuitive that a damaging mutation in MRPS25
would alter the 28S subunit, less expected was the effect on the
39S subunit. In addition to the increase in the 16S rRNA (Fig. 3B),
there was a modest shift in the distribution of the 39S subunits
(Fig. 3C). That this represented a genuine effect of the mutant
was corroborated by the analysis of the mutant fibroblasts com-
plemented with wild-typeMRPS25, where the distribution of the
39S subunits on the sucrose gradientmatched the profile of con-
trol cells (Fig. 6A). Revisiting the literature, we found that other
studies have observed alterations to the 39S subunit stemming
from defects in 28S subunit components, although these were
not always discussed. In transgenic mice mutated for MRPS34,
the abundance of large subunitswas increased in young animals,
and declined in aged tissues, associated with alterations of the
buoyant density of a fraction of the 39S subunit (20). Likewise,
complexomic profiling revealed increased abundance of the 39S
Figure 4. MRPS25 mutation reduced mitochondrial translation and causes a
combined OXPHOS defects in the affected patient. (A) De novo mitochondrial
protein synthesis measured by 35S-methionine incorporation in control (C1) and
patient (P) fibroblasts. The gel image is flanked by polypeptide assignments to
the left and plot profiles showing the pixel intensities for the control (black
line) and patient (P–red line) are shown on the right. Coomassie staining of total
protein was used as loading control. (B) To the left, representative immunoblots
of OXPHOS components of complex I (NDUFA9), complex III (UQCRC1), com-
plex IV (COXII) and complex V (ATP5A). Levels of vinculin (VCL) were used as
indicators of protein loading. To the right, a chart indicating the abundance of
the respiratory chain proteins in the patient fibroblasts compared to controls
(Fiji ImageJ densitometric analysis). The data are the mean± standard error of
the mean of n≥3 independent experiments. Probability was determined using
Welch’s t-test (ns=not significant, P> 0.05; ∗∗∗P< 0.001).
subunit and small changes in its mobility (complex size) in
fibroblasts carrying mutant MRPS2 (3). In addition, as in our
study, a redistribution of the large subunit on sucrose gradients
was observed in fibroblasts with mutant MRPS34 (9). These
alterations to the 39S subunit may reflect abortive attempts to
form the 55S ribosome, or be the result of unstable 55S subunits
breaking apart owing to the distortions created by the mutant
MRPS25.
As with many other mitochondrial diseases, defects in mito-
chondrial translation cause an extremely broad spectrum of
symptoms and signs. Nevertheless, there are some consistent
features among the known mutations in the mitoribosome pro-
teins. The pathological mutation in MRPS25 reported here adds
to those in MRPS16 and MRPS22 that are also associated with
defects of the corpus callosum, which, in the case of theMRPS25
mutant, was partial. Thus, defects in the small subunit of the
mitochondrial ribosome should be considered when defects of
the corpus callosum are present. All three polypeptides are
closely juxtaposed in the 28S subunit (Fig. 7), althoughmutations
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Figure 5. Lentivirus mediated expression of wild-type MRPS25 rescues the mt-
SSU and OXPHOS levels in patient cells. Analysis of the small (MRPS25, MRPS17,
MRPS27, MRPS22) and large (MRPL45) mitochondrial subunits (A) and OXPHOS
components of complex I (NDUFB8), complex III (UQCRC2), complex IV (COXI) (B)
in immortalized cell extracts from control (C1 and C2), patient (P) and patient
transduced with wild-type MRPS25 (PS25). Vinculin (VCL) was used as a loading
control. To the right of A and B, relative abundance of the ribosomal protein
and OXPHOS components in untransduced versus the transduced fibroblasts
(Fiji ImageJ densitometric analysis). The data are shown as the mean± standard
error of themeans of n≥ 3 independent experiments. Probabilitywas determined
using Welch’s t-test (ns =not significant, P> 0.05; ∗P< 0.05).
in MRPS34, immediately adjacent to MRPS16, result in Leigh or
Leigh-like syndrome (9).
Overall, brain involvement (structural or functional) is com-
mon among disorders that arise from mutations in MRPs; in
addition to defects of the corpus callosum and Leigh syndrome,
dilatation of cerebral ventricles and microcephaly have been
reported (7). Cardiomyopathy may also result from mutations in
MRPS genes (7), although it was not evident in our case.
In conclusion, MRP mutants are a rare but rapidly emerg-
ing group of mitochondrial translation disorders, which exhibit
considerable clinical heterogeneity. Although a whole exome or
genome sequencing approach is frequently required to confirm
the diagnosis, early-onset multi-system disease associated with
structural brain disease on MRI should prompt interrogation of
this subset of genes. Moreover, our study indicates that defects
in the translation machinery can result in isolated complex IV
deficiency in muscle, rather than in dysfunction of multiple
respiratory chain enzymes. This observation suggests that dedi-
cated mitochondrial ribosomal proteins regulate the translation
of specific respiratory chain subunits in mammals, as recently
proposed for yeasts (25), providing an explanation of the differ-
entmitochondrial ribosomal profiles among tissues (26), and the
tissue specific manifestations of MRP-related diseases.
Materials and Methods
Samples from the proband and family members were obtained
after receiving written informed consent. The study was
performed in accordance with the Declaration of Helsinki and
approved by our institutional review board.
Figure 6. Rescue of themitoribosomes assembly in patient cells transduced with
wild-type MRPS25. (A) Mitochondrial ribosomes from controls (C1 and C2) and
patient without (P) and with (PS25) wild-type MRPS25 cDNA were sedimented
on sucrose gradient and fractions separated by SDS-PAGE. Mitochondrial ribo-
somal protein markers of the mt-SSU (MRPS27) and the mt-LSU (MRPL13 and
MRPL44) were detected by immunoblotting. The data are representative of two
independent experiments. (B) As in (A), except that MRPS25 protein distribution
was analysed.
Figure 7. The 28S subunit and mitochondrial disease. Schematic representa-
tion of the mitochondrial 28S subunit with circles representing each of the
30 constituent proteins. Numbers in the circles are specific MRPS associated
with mitochondrial disease. Defects in MRPS16, MRPS22 and MRPS25, closely
juxtaposed in the 28S subunit, are associated with agenesis of corpus callosum.
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Histochemical and biochemical studies in skeletal
muscle
Analyses of muscle morphology, histochemistry and respiratory
chain activities were performed as previously described (21,22).
Genetic analysis
DNA was extracted from muscle and peripheral leukocytes
by standard methods. For mtDNA sequencing, 45 overlapping
fragments were amplified and Sanger sequenced using BigDye
Terminator v1.1. Bi-directional sequencing was run on an ABI
3730xl. Data were assembled and analysed by SeqScape v3 using
the revised Cambridge Reference sequence NC_012920.1 for
alignment.
The assessment of large-scale rearrangements of mtDNA,
both single and multiple deletions in muscle, was performed by
long-range polymerase chain reaction (PCR).
Whole exome sequencing was performed on the proband
and parents. The samples were prepared according to an Agi-
lent SureSelect Target Enrichment Kit preparation guide. The
libraries were sequenced with HiSeq 2000/2500 sequencer (Illu-
mina). Sequencing data were aligned to the human reference
genome, hg19 (GRCh37; UCSC genome browser), using Burrows–
Wheeler Alignment Tool and variants were called using GATK.
Filtering of variantswas performedusingVarAft platform (http://
varaft.eu/). We filtered out variants with allele frequency higher
than 1% in gnomAD, 1000 Genome or ESP6500 database, synony-
mous and deep intronic variants. Finally, we prioritized variants
reported in genes listed inmitocarta (23) and variants associated
with the phenotype under study.
Cell culture
Primary skin fibroblast cultures were obtained from healthy
controls and the patient and confirmed free of mycoplasma
based on the LookOut Mycoplasma PCR Detection Kit (Sigma).
Primary fibroblasts were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM, LifeTechnologies) supplemented with 10% fetal
bovine serum (FBS, Hyclone), 1% penicillin and streptomycin (PS,
Life Technologies) at 37◦C in a 5% CO2 atmosphere.
Western blotting and immunodetection
For western blotting, cells were lysed in phosphate buffered
saline (PBS) solution containing 1% SDS, 0.1% n-dodecyl-
D-maltoside (DDM), 1X protease inhibitor cocktail (Roche),
phosphatase inhibitor cocktail (Abcam) and 50 Units Benzonase
(Millipore). Protein concentration was determined by DC
protein assay kit (Biorad). Protein samples were prepared in 1×
Laemmli loading buffer, heated at 42◦C for 15 min and resolved
on SDS-PAGE gels (Novex, Thermofisher Scientific). After
electrophoresis, proteins were transferred to polyvinylidene
fluoride membranes (PVDF, Millipore). Membranes were blocked
with 5% non-fat dry milk in PBS with 0.1% (v/v) Tween-20 (PBST)
and incubated overnight at 4◦C with the primary antibodies
listed in Supplementary Material, Table S2. Membranes were
then washed three times with PBST and incubated with
secondary antibodies conjugated with horseradish peroxidase
(HRP) (Promega) at 1:5000 dilution in 5% milk PBST. After
three washes, immunoblots were developed using enhanced
chemiluminescence (ECL Prime, GE Healthcare).
[35S]-methionine cell labelling for mitochondrial protein
synthesis
Mitochondrial translation products were labelled using 35S-
methionine as previously described (24). Fibroblasts were
washed twice with methionine/cysteine free DMEM (Life
Technologies) supplemented with 1 mM L-glutamax, 96 μg/ml
cysteine (Sigma), 1 mM pyruvate and 5% (v/v) dialyzed FBS,
and incubated in the same medium for 10 min at 37◦C. A
total of 100 μg/ml emetine dihydrochloride (Sigma) was then
added to inhibit cytosolic translation, before pulse-labelling
with 100 μCi [35S]-methionine for 45–60 min. Cells were chased
for 10 min at 37◦C in regular DMEM with 10% FBS, washed
three times with PBS and collected. Labelled cells were lysed
in PBS, 0.1% n-dodecyl-D-maltoside (DDM), 1% SDS, 50 units
Benzonase (Millipore), 1X protease inhibitor cocktail (Roche).
Protein concentration was measured by DC protein assay kit
(Biorad) and 20 μg of protein were separated by 12% SDS-PAGE.
Gel were fixed and vacuum dried, and exposed to X-ray film for
1 week.
RNA quantification
Total RNA was isolated from controls and patient fibroblasts
using Pure LinkTM RNA Mini Kit (Ambion). Quantitative reverse
transcription polymerase chain reaction (RT-PCR)was performed
in triplicate on 384-Well reaction plates using a 7900HT Fast
Real-Time PCR System (Applied Biosystems). Fifty-nanogram
total RNA was retro-transcribed and amplified in ‘one-step’
reactions using QuantiFast SYBR Green RT-PCR Kit (QIAGEN).
Expression of 12S and 16S rRNA was normalized to expression
of the housekeeping ß-actin gene (ACTB) and results were
represented as fold changes in the patient relative to controls.
Primer-sequences are listed in SupplementaryMaterial, Table S3.
Sucrose gradient sedimentation
A total of 5×106 fibroblasts were lysed in 700 ul of lysis buffer
(40 mM Tris-HCl, pH 7.6, 150 mM NaCl, 20 mM MgCl2, 1% n-
dodecyl-D-maltoside (DDM), 1 mM PMSF, 1X protease inhibitors
without EDTA, 0.08 U/mL RNasin) on ice for 45 min. Lysates were
cleared by centrifugation at 12 000× g for 40 min and 1 mg lots
of protein were loaded onto a 10–30% linear sucrose gradient.
Gradientswere prepared in 40mMTris-HCl, 150mMNaCl, 20mM
MgCl2, 1 mM PMSF, 1X protease inhibitors without EDTA, using
a gradient master (Biocomp), according to the manufacturer
instructions. Samples were centrifuged at 71 000× g for 16 h in
a Beckman SW41 rotor at 4◦C. After centrifugation, 16 fractions
of 750 μl each were collected from the top of the gradient and
analysed by immunoblotting. For MRPS25 analysis, the protein
content of each fractionwas concentrated by trichloroacetic acid
(TCA) precipitation before western blot analysis.
Lentiviral expression of wild-type MRPS25
MRPS25 cDNA clone (BC003590.2) was obtained from BioCat
GmbH (Heidelberg, Germany). A MRPS25-Flag construct was
generated with a pair of oligonucleotides (forward primer: 5′- Ctt
ctt Gaa Ttc acc atg cccatgaagggccgcttccccatc -3′, reverse primer:
5′- ctctct aagctt cta cttatcgtcgtcatccttgtaatc gtcctgggcatcggctttca-
3′), which include EcoRI and HindIII restriction sites and the
Flag tag, and was inserted into pENTR vector (Life Technologies,
Darmstadt, Germany). After generating an entry clone, the
pLenti CMV Blast DESTMRPS25-Flag expressing vector (Addgene
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plasmid #17451) was created using LR recombination. The
pLenti CMV Blast DEST MRPS25-Flag expressing vector and
packaging plasmids pMD2.G and psPAX2 (Addgene plasmid
#12259 and #12260) were transfected into HEK-293FT cells
with lipofectamin 2000 (Life Technologies, ThermoFisher
Scientific, Darmstadt, Germany) and OPTI-MEM media (Life
Technologies, ThermoFisher Scientific, Darmstadt, Germany)
to produce the lentivirus. The recombinant lentiviral constructs
were transduced into the fibroblast cell lines that had been
immortalized by retroviral expression of the HPV-16 E6E7 gene.
Stable cell lines expressing the MRPS25-Flag protein were
generated by blasticidin (Invitrogen) selection.
Modelling of human MRPS25
Multiple sequence alignment was done using the Clustal Omega
(https://www.ebi.ac.uk/Tools/msa). The structural model image
was prepared with the PyMOL Molecular Graphics System, Ver-
sion 1.2r3pre, Schrödinger, LLC.
Statistics
Statistical analyses were performed using Graphpad Prism
v.7.04. Immunoblots and mitochondrial protein synthesis were
analyzed with Fiji ImageJ. T-test was used for comparing two
independent groups. P-values <0.05 were considered to be
statistically significant.
Supplementary Material
Supplementary Material is available at HMG online.
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